echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA: The effect of celecoxib combined with FOLFOX standard adjuvant chemotherapy on the disease-free survival rate of colon cancer patients

    JAMA: The effect of celecoxib combined with FOLFOX standard adjuvant chemotherapy on the disease-free survival rate of colon cancer patients

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Although the prevention and treatment of colorectal cancer has made significant progress, in 2021 the United States is expected to die from colorectal cancer to 52,980, and the global death toll from colorectal cancer will exceed 915,880.


    Colorectal cancer prevention

    Recently, researchers investigated the effect of adding celecoxib to the adjuvant chemotherapy regimen of fluorouracil, calcium leucovorin and oxaliplatin (FOLFOX) on the disease-free survival rate of patients with stage III colon cancer .


    Recently, researchers investigated the effect of adding celecoxib to the adjuvant chemotherapy regimen of fluorouracil, calcium leucovorin and oxaliplatin (FOLFOX) on the disease-free survival rate of patients with stage III colon cancer .


    This phase III clinical study was carried out in the United States and Canada.


    medsci.


    The 3-year disease-free survival rate of patients in the celecoxib group was 76.


    Differences in disease-free survival and overall survival between groups

    For patients with stage III colon cancer, adding celecoxib to the FOLFOX standard adjuvant chemotherapy regimen has no effect on the 3-year disease-free survival rate of patients .


    For patients with stage III colon cancer, adding celecoxib to the FOLFOX standard adjuvant chemotherapy regimen does not improve the patient's 3-year disease-free survival rate.


    Original source

    Jeffrey A.


    com/journals/jama/article-abstract/2778113" target="_blank" rel="noopener">Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
    JAMA

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.